Hookipa Pharma (NASDAQ:HOOK) Shares Down 4.8% – Time to Sell?

Shares of Hookipa Pharma Inc (NASDAQ:HOOK) were down 4.8% during trading on Wednesday . The company traded as low as $1.78 and last traded at $1.79. Approximately 47,510 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 173,485 shares. The stock had previously closed at $1.88.

Wall Street Analyst Weigh In

A number of analysts have commented on HOOK shares. Royal Bank of Canada downgraded shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $48.00 to $2.00 in a report on Friday, December 20th. JMP Securities cut their price objective on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright reiterated a “neutral” rating on shares of Hookipa Pharma in a report on Friday, January 10th.

Hookipa Pharma Stock Performance

The firm’s 50 day moving average price is $1.95 and its two-hundred day moving average price is $3.30. The firm has a market cap of $21.59 million, a PE ratio of -0.48 and a beta of 0.72.

Institutional Trading of Hookipa Pharma

Hedge funds have recently made changes to their positions in the company. Ikarian Capital LLC purchased a new position in shares of Hookipa Pharma during the 3rd quarter worth approximately $228,000. Millennium Management LLC purchased a new position in Hookipa Pharma in the 4th quarter valued at approximately $31,000. Squarepoint Ops LLC purchased a new position in Hookipa Pharma in the 4th quarter valued at approximately $104,000. Finally, Gilead Sciences Inc. purchased a new position in Hookipa Pharma in the 4th quarter valued at approximately $3,771,000. Hedge funds and other institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.